T cells expressing anti-CD3 antibodies autoactivate and decrease expression of T cell receptors to treat GVHD, or make T cells suitable for off-the-shelf treatment of allogeneic subjects
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE
Contact
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596
21MA013N
